KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Jazz Pharmaceuticals (JAZZ) Asset Writedowns and Impairment (2018 - 2023)

Jazz Pharmaceuticals has reported Asset Writedowns and Impairment over the past 6 years, most recently at $61.0 million for Q4 2023.

Quarterly results put Asset Writedowns and Impairment at $61.0 million for Q4 2023, changed N/A from a year ago — trailing twelve months through Dec 2023 was $194.7 million (up 45.65% YoY), and the annual figure for FY2023 was $61.0 million, down 54.35%.
Asset Writedowns and Impairment for Q4 2023 was $61.0 million at Jazz Pharmaceuticals, down from $133.6 million in the prior quarter.
Over the last five years, Asset Writedowns and Impairment for JAZZ hit a ceiling of $136.1 million in Q1 2020 and a floor of $61.0 million in Q4 2023.
Median Asset Writedowns and Impairment over the past 3 years was $133.6 million (2022), compared with a mean of $110.3 million.